Cmvpp65 a0201 peptide vaccine
Cmvpp65 a0201 peptide vaccine - a peptide based cancer vaccine containing a mutated form of the hla a0201 restricted cytomegaloviral epitope cmvpp65(495 503) with potential immunostimulatory and antitumor activities. Upon subcutaneous administration, cmvpp65 a0201 peptide vaccine may stimulate a cytotoxic t lymphocyte (ctl) response against cmv positive cells, resulting in cell lysis. Hla a0201 is an mhc class I molecule that presents antigenic peptides to cd8+ t cells; epitope design restricted to epitopes that bind most efficiently to hla a0201 may improve antigenic peptide immunogenicity. Cmvpp65, a tegument protein of the herpes virus cmv, is the main viral antigen found in peripheral blood mononuclear cells (pbmcs) after viral infection and may activate cell mediated immunity.
Latest articles Cmvpp65 a0201 peptide vaccine
|This medical article is a stub. You can help WikiMD by expanding it.|
Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on Cmvpp65 a0201 peptide vaccine for any updates.